Examining the link between skin bacteria and radiation dermatitis in breast cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on breast cancer patients who have undergone mastectomy and breast reconstruction followed by radiotherapy. It aims to systematically analyze the skin microbiome before and after radiotherapy to determine its association with the severity of radiation dermatitis. Given that a significant percentage of patients experience radiation dermatitis, understanding the role of the skin microbiome could provide insights into improving patient care. The study seeks to deepen the understanding of how skin microbiota interacts with skin physiology and immune responses during treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female patients
2. Invasive breast cancer confirmed by pathology
3. Underwent mastectomy and breast reconstruction
4. Radiotherapy after breast reconstruction
5. ECOG score 0-1
6. Signed informed consent

Exclusion Criteria:

1. Previous breast or chest radiotherapy
2. Other serious skin diseases (systemic lupus erythematosus, skin sclerosis, et al) and cannot receive radiotherapy
3. Pregnant women
4. Patients who are unwilling or unable to receive regular follow-up.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Xiaoli Yu, MD, Ph.D — Fudan University
• Study coordinator: Wei Shi, MD, Ph.D
• Email: wei.shi118@foxmail.com
• Phone: +86 18121299680

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Skin-repair cream to prevent radiation dermatitis after breast cancer surgery

  This phase 3 trial tests whether a natural weak-acid skin repair cream can prevent acute radiation dermatitis in adults who had mastectomy and are receiving adjuvant radiotherapy for breast cancer.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07066280

• Mepitel Film for Preventing Radiation Dermatitis in Breast Cancer Patients in Singapore

  This observational study tests whether Mepitel Film can help prevent radiation dermatitis in breast cancer patients getting whole breast or chest wall radiotherapy in Singapore.

  Recruiting National University Hospital, Singapore · Singapore · NCT07729423

• Comparing Betamethasone and Moisturizer for Skin Care in Breast Cancer Patients

  This study is testing whether a skin cream called betamethasone can help prevent skin problems from radiation therapy in large-breasted breast cancer patients compared to using just a moisturizer.

  Recruiting Phase 3 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT06915857

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.